Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with kidney disease. Headquartered in Cambridge, Massachusetts, the company specializes in treatments based on hypoxia-inducible factor (HIF) biology and complement inhibition. Its commercial portfolio primarily targets complications of chronic kidney disease, such as anemia and hyperphosphatemia.

Financials

Earnings Transcripts

Leadership & board

Acquisitions

Akebia is a clinical- and commercial-stage biopharmaceutical company that has not authorized a common-stock repurchase program; the FY2025 10-K discloses no share-repurchase or buyback activity (the company has historically funded operations through equity and debt financings rather than returning capital to shareholders).

Revenue is highly concentrated among a few dialysis organizations and distributors: in fiscal 2025, Fresenius Medical Care Rx accounted for 30%, U.S. Renal Care 29%, and DaVita, Inc. 25% of total gross revenues from Auryxia and Vafseo, and these three dialysis organizations together represented a significant percentage of gross revenue.

You're subscribed.

Thanks for signing up.